<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633399</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-002361</org_study_id>
    <nct_id>NCT00633399</nct_id>
  </id_info>
  <brief_title>Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs</brief_title>
  <official_title>A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if adding the study drug, ziprasidone, to an
      antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD). We are
      studying the drug's effectiveness in treating depression, as well as its safety when it is
      added to another drug.

      Hypothesis A: There will be a difference in the percentage of responders in the two treatment
      conditions during phase 2; response rates will be higher for the ziprasidone group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study involves three phases. The first phase is an 8-week, open-label trial of
      an SSRI for MDD. Patients who do not experience sufficient symptom improvement following this
      open-label trial will be enrolled in a 6-week, double-blind, placebo controlled trial of
      ziprasidone augmentation (second phase). Ziprasidone and placebo-remitters will then enter a
      12-month, double-blind extension phase (third phase). We estimate that approximately 400
      patients will enter phase 1 of the study so that a minimum of 180 subjects will enter
      double-blind treatment (phase 2) over 5 years. Each treatment arm during phase 2 will have 90
      subjects.

      Hypothesis B1: During phase 2, there will be a difference between the two groups in the
      percentage of responders (50% or greater reduction in symptom severity) with regards to
      anxious symptoms of MDD as measured by the 14-item Hamilton Anxiety Rating Scale (HAM-A);
      response rates will be higher for the ziprasidone group.

      Hypothesis B2: During phase 2, there will be a difference between the two groups in the
      percentage of responders (50% or greater reduction in symptom severity) with regards to
      painful symptoms of MDD, as measured by the overall visual analogue pain (VAS-pain) scale
      scores; response rates will be higher for the ziprasidone group.

      Hypothesis C: The time to relapse during phase 3 will be shorter among adjunctive placebo-
      than ziprasidone-remitters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2</measure>
    <time_frame>8 Weeks</time_frame>
    <description>The primary outcome measure will be response rates (50% decrease in HAM-D-17 scores) during phase 2. A responder will be a patient who experiences a 50% or greater decrease in symptoms according to the HAM-D-17 during phase 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.</measure>
    <time_frame>8 weeks</time_frame>
    <description>A secondary outcome measure will be remission rates (HAM-D 17 scores of less than 8) after treatment phase 2.. A remitted will be a patient with a final score of 7 or less on the HAMD-17 during phase 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>This will involve looking at the change in HAM-D 17 scores during phase 2. For HAMD-17 the minimum is 0, the maximum is 52, and greater scores represent more symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0mg Placebo per day (1-4 tablets per day). &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Men or women, 18-65 years of age.

          -  MDD, current, according to DSM-IV criteria and as diagnosed by the SCID- I/P during
             the screen and baseline visit of phase 1.

          -  A HAM-D-17 score &gt; 14 during the screen and baseline visit of phase 1.

        Exclusion Criteria:

          -  Pregnant women or women of child bearing potential who are not using a medically
             accepted means of contraception (oral contraceptive or implant, condom, diaphragm,
             spermicide, intrauterine

          -  Device, tubal ligation, or partner with vasectomy).

          -  Serious suicide or homicide risk, as assessed by evaluating clinician.

          -  Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
             endocrine, neurological, or hematological disease or uncontrolled seizure disorder.

          -  History of multiple adverse drug reactions or allergy to the study drug.

          -  The following DSM-IV diagnoses: substance use disorders active within the last six
             months, any bipolar disorder (current or past), any psychotic disorder (current or
             past).

          -  Patients requiring excluded medications (see appendix 1 for details).

          -  Psychotic features in the current episode or a history of psychotic features.

          -  Prior course of ziprasidone, or intolerance to ziprasidone at any dose.

          -  Any investigational psychotropic drug within the last 3 months.

          -  Have failed more than 3 adequate antidepressant trials during the current MDE. Some
             examples of adequate dosage of an antidepressant trial include either &gt; 150 mg of
             imipramine (or its tricyclic equivalent), &gt; 60 mg of phenelzine (or its monoamine
             oxidase inhibitor equivalent), &gt; 20 mg of fluoxetine (or its SSRI-equivalent), &gt; 150mg
             of bupropion, &gt; 300mg of trazodone (or nefazodone), &gt;75 mg of venlafaxine, &gt;60mg of
             duloxetine, or &gt; 15mg of mirtazapine. A trial of adequate duration was defined as one
             during which the patient was on any given antidepressant at an adequate dose for a
             minimum of 6 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George I Papakostas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital- Depression Clinical and Research Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <results_first_submitted>June 24, 2014</results_first_submitted>
  <results_first_submitted_qc>June 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2014</results_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>George I. Papakostas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Major Depression</keyword>
  <keyword>Depression</keyword>
  <keyword>Geodon</keyword>
  <keyword>Ziprasidone</keyword>
  <keyword>SSRI Augmentation</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>458 patients met eligibility criteria for the study and were enrolled in an 8-week, open-label, flexible dose trial of escitalopram. At the end of this open-label trial, 139 patients not responding to Escitalopram were randomized to receive adjunctive ziprasidone or adjunctive placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ziprasidone + Escitalopram</title>
          <description>Patients in group 1 will receive Ziprasidone added to Escitalopram for the full 8 weeks of Phase 2.
Ziprasidone: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Escitalopram</title>
          <description>Patients in group 2 will receive Placebo added to Escitalopram for the full 8 weeks of Phase 2.
Placebo: 0mg Placebo per day (1-4 tablets per day). &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ziprasidone + Escitalopram</title>
          <description>Patients in group 1 will receive Ziprasidone added to Escitalopram for the full 8 weeks of Phase 2.
Ziprasidone: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Escitalopram</title>
          <description>Patients in group 2 will receive Placebo added to Escitalopram for the full 8 weeks of Phase 2.
Placebo: 0mg Placebo per day (1-4 tablets per day). &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="13.8"/>
                    <measurement group_id="B2" value="44.2" spread="11.0"/>
                    <measurement group_id="B3" value="44.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2</title>
        <description>The primary outcome measure will be response rates (50% decrease in HAM-D-17 scores) during phase 2. A responder will be a patient who experiences a 50% or greater decrease in symptoms according to the HAM-D-17 during phase 2.</description>
        <time_frame>8 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone + Escitalopram</title>
            <description>Patients in group 1 will receive Ziprasidone added to Escitalopram for the full 8 weeks of Phase 2.
Ziprasidone: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Escitalopram</title>
            <description>Patients in group 2 will receive Placebo added to Escitalopram for the full 8 weeks of Phase 2.
Placebo: 0mg Placebo per day (1-4 tablets per day). &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2</title>
          <description>The primary outcome measure will be response rates (50% decrease in HAM-D-17 scores) during phase 2. A responder will be a patient who experiences a 50% or greater decrease in symptoms according to the HAM-D-17 during phase 2.</description>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.</title>
        <description>A secondary outcome measure will be remission rates (HAM-D 17 scores of less than 8) after treatment phase 2.. A remitted will be a patient with a final score of 7 or less on the HAMD-17 during phase 2.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone + Escitalopram</title>
            <description>Patients in group 1 will receive Ziprasidone added to Escitalopram for the full 8 weeks of Phase 2.
Ziprasidone: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Escitalopram</title>
            <description>Patients in group 2 will receive Placebo added to Escitalopram for the full 8 weeks of Phase 2.
Placebo: 0mg Placebo per day (1-4 tablets per day). &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.</title>
          <description>A secondary outcome measure will be remission rates (HAM-D 17 scores of less than 8) after treatment phase 2.. A remitted will be a patient with a final score of 7 or less on the HAMD-17 during phase 2.</description>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8</title>
        <description>This will involve looking at the change in HAM-D 17 scores during phase 2. For HAMD-17 the minimum is 0, the maximum is 52, and greater scores represent more symptoms.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone + Escitalopram</title>
            <description>Patients in group 1 will receive Ziprasidone added to Escitalopram for the full 8 weeks of Phase 2.
Ziprasidone: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Escitalopram</title>
            <description>Patients in group 2 will receive Placebo added to Escitalopram for the full 8 weeks of Phase 2.
Placebo: 0mg Placebo per day (1-4 tablets per day). &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8</title>
          <description>This will involve looking at the change in HAM-D 17 scores during phase 2. For HAMD-17 the minimum is 0, the maximum is 52, and greater scores represent more symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="6.4"/>
                    <measurement group_id="O2" value="-3.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone + Escitalpram</title>
          <description>Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2.
Ziprasidone: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
        </group>
        <group group_id="E2">
          <title>Ziprasidone + Placebo</title>
          <description>Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2.
Placebo: 0mg Placebo per day (1-4 tablets per day). &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>GI Upset</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence and/or Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="71"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Poor concentration and/or memory</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Anxiety and/or Agitation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Muscle Twitching</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Sexual Dysfunction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George I Papakostas, M.D. - Scientific Director</name_or_title>
      <organization>Massachusetts General Hospital CNTI</organization>
      <phone>6177266697</phone>
      <email>gpapakostas@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

